Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
3859957
Reference Type
Journal Article
Subtype
Abstract
Title
Perfluorohexanesulfonate and perfluorooctanesulfonate decrease plasma cholesterol and triglycerides in APOE*3Leiden transgenic mice. Indication for a PPARα agonist mechanism
Author(s)
Pieterman, E; van den Hoek, AM; Havekes, LM; Ehresman, DJ; Chang, S; Butenhoff, JL; Princen, HM; Cohen, LH
Year
2007
Is Peer Reviewed?
0
Journal
Atherosclerosis. Supplements
ISSN:
1567-5688
EISSN:
1878-5050
Volume
8
Issue
1
Page Numbers
41
Language
English
DOI
10.1016/S1567-5688(07)71108-X
Web of Science Id
WOS:000247869100162
Abstract
Objective: Perfluorinated alkyl sulphonates are fully fluorinated amphiphilic organic molecules with strong surface-tension reducing properties. They are stable to environmental and metabolic degradation. Perfluorooctanesulfonate (PFOS) is widely dispersed in humans, fish-eating wildlife, and surface waters. Toxicological studies in rats and monkeys have shown a reduction in serum cholesterol after treatment with PFOS; however, such reductions have not been observed among exposed workers. In the present study we investigated the mechanistical background of the effect of perfluorobutanesulfonate (PFBS), perfluorohexanesulfonate (PFHS) and PFOS on cholesterol and triglyceride metabolism in APOE*3Leiden transgenic mice (a mouse model with a human-like lipoprotein profile).
Methods and Results: Whereas PFBS treatment (30 mg/kg/day) had no effect, both PFHS (6 mg/kg/day) and PFOS (3 mg/kg/day) reduced plasma cholesterol (-36% and -31%) and triglycerides (-50% and -22%) in APOE*3Leiden mice, by a decrease in VLDL/IDL, and caused a concomitant shift of HDL towards larger particles. Mice treated for 10 weeks with PFHS and PFOS had increased ALAT levels (2-5 fold), enlarged livers (2-3 fold) and reduced cholesterol 7-α-hydroxylase activities (-60% and -77%) with a decreased fecal excretion of bile acids (-25% and -48%). Furthermore, PFHS and PFOS showed elevated plasma ketone bodies (2-3 fold), decreased respiratory exchange ratios, increased amounts of liver mitochondria and loss of perigonadal fat, all indicative of an increased fatty acid oxidation.
Conclusions: Treatment of APOE*3Leiden mice with PFHS and PFOS results in reduced plasma cholesterol and triglycerides, increased liver size, decreased cholesterol 7-α-hydroxylase and increased fatty acid oxidation, suggesting a PPARα agonist activity.
Conference Name
76th Congress of the European Atherosclerosis Society
Conference Location
Helsinki, Finland
Conference Dates
June 10-13, 2007
Tags
PFAS
•
^Per- and Polyfluoroalkyl Substances (PFAS)
PFHxS (355-46-4)
Literature search
WOS
•
PFAS Universe
Data Source
Web of Science
Screened Studies
Excluded
Exclude (TIAB)
Perfluorohexanesulfonate
Perfluorohexanesulfonic acid
Perfluorooctanesulfonate
Perfluorooctanesulfonic acid
•
PFBA
Protocol References
•
PFHxS
Database searches
WOS
Excluded
TiAb
•
Yale PFAS Liver study
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity